menu

Neurotrophic Keratitis: Evolving Staging System and Emerging Agents

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Neurotrophic Keratitis: Evolving Staging System and Emerging Agents

4 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Management of neurotrophic keratitis (NK) is based on disease severity. During this webinar, the faculty members discuss updated viewpoints on what truly constitutes stage 1 disease as well as NK diagnostic strategies, treatment of stage 1 NK to prevent progression, and novel therapies.

    This content was captured during a synchronous virtual symposium. Polling took place during the symposium.

  • Disclosure of Conflicts of Interest

    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    John A. Hovanesian, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Acufocus, Aerie Pharmaceuticals, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, Bausch + Lomb, BlephEx, Carl Zeiss Meditec, Cloudbreak Therapeutix, Cord, ECRI, Eyedetec, EyePoint, Glaukos, Glaxo Smithkline, Glint Pharma, Gobiquity, Guardion Health Sciences, Imprimis, Ingenoeye, Johnson & Johnson Vision, Kala Pharmaceuticals, MDbackline, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis Pharmaceuticals, Oyster Point Pharma, Research InSight, Sensimed, Sight Sciences, SightLife, Sun Pharma, Tarsus Pharmaceuticals, TearLab, Touch Ophthalmology, Vindico Medical Education, and Visus. Grant/Research Support: Acufocus, Aerie Pharmaceuticals, Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Cord, EyePoint, Glaukos, Imprimis, Ingenoeye, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, On Point Vision, Research InSight, Sight Sciences, and Sun Pharma. Stock/Shareholder: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Cloudbreak Therapeutix, Cord, Corneagen, Crisper, Equinox, Eyedetec, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Ingenoeye, Johnson & Johnson Vision, MDbackline, Novartis, Ocular Therapeutix, Orasis Pharmaceuticals, Research InSight, RxSight, Sight Sciences, Tarsus Pharmaceuticals, TearClear, Versant Ventures and its investments, and Visionary Ventures Fund 1 and 2 and its investments. Royalties: Slack Books.

    Frank W. Bowden III, MD, FACS, has had a finacial relationship or affiliation with the following ineligible companies in the form of Speaker's Bureau: Bausch + Lomb and Sun Pharma.

    Jennifer Loh, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Centricity Vision, Dompé, Horizon, Johnson & Johnson Vision, Kala Pharmaceuticals, Lensar, Novartis, Omeros, Orasis Pharmaceuticals, OSRX, Sight Sciences, Sun Pharma, Tarsus Pharmaceuticals, and Visus. Grant/Research Support: Sight Sciences. Shareholder: Novabay. Speaker's Bureau: Alcon, Allergan, Bausch + Lomb, Sight Sciences, and Sun Pharma.

    Kelly K. Nichols, OD, MPH, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Aerie Pharmaceuticals, Alcon, Alderya, Allergan, Axim, Azura Ophthalmics, Bausch + Lomb, Bruder Healthcare, Cavalry, Dompé, HanAll Biopharma, Nicox, Novaliq, Novartis, Osmotica, Oyster Point Pharma, Palatin Technologies, RVL, Shire, Tarsus Pharmaceuticals, Takeda, TearSolutions, Théa Pharma, TopiVert, Trukera Medical, Verséa Health, and Xequel. Grant/Research Support: Aramis, Kowa, ScienceBased Health, TearScience, and Sylentis.

    The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Explain diagnostic strategies for neurotrophic keratitis (NK) and identify patients with stage 1 disease
    • Describe current and emerging treatment options for stage 1 NK
    • Develop personalized treatment plans for patients with stage 1 NK
    • Discuss new data on novel treatments for NK and how it compares to traditional treatments
  • Target Audience

    This certified continuing medical education activity is designed for optometrists and general ophthalmologists.

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)


    Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.

  • Commercial Support

    This activity is supported by an unrestricted educational grant from Dompé.

  • Disclaimer

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Dompé.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Management of neurotrophic keratitis (NK) is based on disease severity. During this webinar, the faculty members discuss updated viewpoints on what truly constitutes stage 1 disease as well as NK diagnostic strategies, treatment of stage 1 NK to prevent progression, and novel therapies.

    This content was captured during a synchronous virtual symposium. Polling took place during the symposium.

  • Disclosure of Conflicts of Interest

    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    John A. Hovanesian, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Acufocus, Aerie Pharmaceuticals, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, Bausch + Lomb, BlephEx, Carl Zeiss Meditec, Cloudbreak Therapeutix, Cord, ECRI, Eyedetec, EyePoint, Glaukos, Glaxo Smithkline, Glint Pharma, Gobiquity, Guardion Health Sciences, Imprimis, Ingenoeye, Johnson & Johnson Vision, Kala Pharmaceuticals, MDbackline, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis Pharmaceuticals, Oyster Point Pharma, Research InSight, Sensimed, Sight Sciences, SightLife, Sun Pharma, Tarsus Pharmaceuticals, TearLab, Touch Ophthalmology, Vindico Medical Education, and Visus. Grant/Research Support: Acufocus, Aerie Pharmaceuticals, Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Cord, EyePoint, Glaukos, Imprimis, Ingenoeye, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, On Point Vision, Research InSight, Sight Sciences, and Sun Pharma. Stock/Shareholder: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Cloudbreak Therapeutix, Cord, Corneagen, Crisper, Equinox, Eyedetec, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Ingenoeye, Johnson & Johnson Vision, MDbackline, Novartis, Ocular Therapeutix, Orasis Pharmaceuticals, Research InSight, RxSight, Sight Sciences, Tarsus Pharmaceuticals, TearClear, Versant Ventures and its investments, and Visionary Ventures Fund 1 and 2 and its investments. Royalties: Slack Books.

    Frank W. Bowden III, MD, FACS, has had a finacial relationship or affiliation with the following ineligible companies in the form of Speaker's Bureau: Bausch + Lomb and Sun Pharma.

    Jennifer Loh, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Centricity Vision, Dompé, Horizon, Johnson & Johnson Vision, Kala Pharmaceuticals, Lensar, Novartis, Omeros, Orasis Pharmaceuticals, OSRX, Sight Sciences, Sun Pharma, Tarsus Pharmaceuticals, and Visus. Grant/Research Support: Sight Sciences. Shareholder: Novabay. Speaker's Bureau: Alcon, Allergan, Bausch + Lomb, Sight Sciences, and Sun Pharma.

    Kelly K. Nichols, OD, MPH, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Aerie Pharmaceuticals, Alcon, Alderya, Allergan, Axim, Azura Ophthalmics, Bausch + Lomb, Bruder Healthcare, Cavalry, Dompé, HanAll Biopharma, Nicox, Novaliq, Novartis, Osmotica, Oyster Point Pharma, Palatin Technologies, RVL, Shire, Tarsus Pharmaceuticals, Takeda, TearSolutions, Théa Pharma, TopiVert, Trukera Medical, Verséa Health, and Xequel. Grant/Research Support: Aramis, Kowa, ScienceBased Health, TearScience, and Sylentis.

    The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Explain diagnostic strategies for neurotrophic keratitis (NK) and identify patients with stage 1 disease
    • Describe current and emerging treatment options for stage 1 NK
    • Develop personalized treatment plans for patients with stage 1 NK
    • Discuss new data on novel treatments for NK and how it compares to traditional treatments
  • Target Audience

    This certified continuing medical education activity is designed for optometrists and general ophthalmologists.

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)


    Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.

  • Commercial Support

    This activity is supported by an unrestricted educational grant from Dompé.

  • Disclaimer

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Dompé.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Apr 2024